Related Experiment Videos
Midazolam dosage studies in institutionalized geriatric patients
British Journal of Clinical Pharmacology
|January 1, 1983
Summary
Midazolam effectively treats insomnia in geriatric patients, shortening sleep onset and increasing total sleep time. Doses of 7.5 mg and 15 mg showed significant hypnotic efficacy with a wide safety margin.
Area of Science:
- Pharmacology
- Geriatric Medicine
- Sleep Medicine
Background:
- Insomnia is a prevalent issue in institutionalized geriatric populations.
- Long-standing insomnia in the elderly requires effective and safe treatment options.
Purpose of the Study:
- To evaluate the hypnotic efficacy and safety of different midazolam dosages in geriatric patients with chronic insomnia.
- To determine the minimum effective dose and maximum tolerated dose of midazolam for this population.
Main Methods:
- Three studies were conducted involving 47 institutionalized geriatric patients.
- Study I: Double-blind, cross-over trial comparing midazolam (7.5 mg and 15 mg) versus placebo.
- Study II: Comparative cross-over trial of midazolam (7.5 mg) versus oxazepam (25 mg). Study III: Investigated individual dose limits.
Main Results:
- Both 7.5 mg and 15 mg midazolam significantly shortened sleep onset latency and increased total sleep time compared to placebo.
- Midazolam (7.5 mg) was effective in reducing sleep onset time in 66/70 nights, outperforming oxazepam (53/70 nights).
- The minimum effective dose was 7.5 mg, with an optimal dose of 15 mg for most patients. High doses showed a wide safety margin.
Conclusions:
- Midazolam demonstrates significant hypnotic efficacy in geriatric patients with chronic insomnia.
- A dosage range of 7.5 mg to 15 mg appears optimal for treating insomnia in this demographic.
- Midazolam exhibits a favorable safety profile with minimal residual sedative effects at effective doses.